Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ALGN — frequently asked questions
Is Align Technology Inc. overvalued?
In our latest published analysis dated 2026-09-20, ALGN looks meaningfully overvalued. The price recorded at analysis is USD 148 versus our fair value of USD 121; the high endpoint is presented separately as potential value of USD 121. That implies roughly 17.8% downside to fair value at that date.
Our latest published report, analyzed 2026-09-20, gives ALGN a fair value of USD 121 and a potential value of USD 121. The conclusion is triangulated across multiple valuation models and weighted by reliability for Align Technology Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ALGN now?
Our latest published rating for ALGN, analyzed 2026-09-20, is Reduce. Align Technology Inc. looks meaningfully overvalued at the analysis-date price of USD 148 versus fair value of USD 121; potential value is USD 121. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ALGN?
The dedicated bear-case section in our report analyzed 2026-09-20 documents Align Technology Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ALGN's rating?
Our latest published rating for ALGN, analyzed 2026-09-20, is Reduce, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of USD 121, the potential value of USD 121, and the price recorded at analysis (USD 148).
Este relatório ainda não foi traduzido. Atualize em alguns minutos assim que a fila de tradução recuperar o atraso.
§1 Resumo executivoEN
Resposta em 30 segundosReduce
Preço versus valor
Preço
$147.61
Valor justo
$121.31
Valor potencial
$121.34
Em
2026-09-18
Por que pode funcionar
Accelerating clear aligner adoption among teenagers and expanding iTero digital scanner installations across underpenetrated European and Asia-Pacific dental channels, driving top-line revenue growth toward 6% and operating margins toward 18% as manufacturing automation in Poland scales.
We rate Align Technology as Reduce. The stock trades above our estimate of intrinsic value, suggesting investors should trim existing positions and defer new purchases.
A Reduce rating indicates that the shares offer an unattractive risk-reward profile at prevailing market levels. For an ordinary investor, this means capital is better preserved elsewhere, and existing holdings should be trimmed rather than expanded.
The report was prepared at a price of $147.61 on September 18, 2026. This price stands 21.7% above our Fair value of $121.31 and exceeds our Potential value of $121.34. With the shares trading above both benchmarks, the current valuation provides no margin of safety against operational or macroeconomic setbacks.
The primary risk to our outlook is a worsening consumer spending environment that prompts adult patients to postpone elective, out-of-pocket orthodontic treatments. If this occurs, investors would observe Clear Aligner segment revenue growth turning negative year over year. Combined with substantial unallocated corporate overhead, falling case volumes would compress consolidated operating margins below 11.0% and severely impair free cash flow generation.6,7
Conversely, the primary path for business outperformance relies on accelerated clear aligner adoption among teenagers and international dental practices. If next-generation iTero scanner placements increase case starts across underpenetrated overseas markets, sales growth would re-accelerate and fixed manufacturing costs would be absorbed more efficiently. Higher operating cash flows would then support value per share approaching our Potential value of $121.34, though this remains secondary to the downside risks at the report-date price.7
Switching Costs
Over 18 million cumulative patients treated and extensive dental practice integration with ClinCheck software and iTero intraoral scanners create substantial switching costs for dental professionals.7
Proprietary SmartTrack material patents and Invisalign brand recognition allow Align to sustain FY2025 gross margins of 67.19%, maintaining a 1,319 bps premium over the healthcare products industry average of 54.00%.6
Network Effects
An international installation base across Europe and Asia-Pacific generated $2,373.78M in FY2025 international revenue, reinforcing scanner network adoption and clinical case data feedback loops.7
Recomendação da casa
We rate Align Technology as Reduce because the report-date price of $147.61 sits well above our Fair value of $121.31 while unallocated corporate overhead and slowing elective dental procedure growth constrain operating earnings.
Visão geral da empresa
ALIGN TECHNOLOGY, INC. has two operating segments: (1) Clear Aligner and (2) Imaging Systems and CAD/CAM Services (“Systems and Services”). For the year ended December 31, 2025, Clear Aligner net revenues represented approximately 80% of worldwide net revenues, while Systems and Services net revenues represented the remaining 20%. ALIGN TECHNOLOGY, INC. sells the majority of its products and services directly through a dedicated and specialized sales force to its customers: orthodontists, GPs, including prosthodontists, periodontists, oral surgeons and dental laboratories. General economic conditions impact its business and financial results, and the company has historically experienced seasonal trends within its two operating segments, customer channels and geographic locations the company serves. Sales of the Invisalign System are often weaker in Europe, especially southern European countries during the summer months and seasonally higher in China during the third quarter.
Similarly, other international holidays like Lunar New Year can impact its sales in APAC in the first quarter. Income from operations for each segment includes all geographic revenues, related cost of net revenues and operating expenses directly attributable to the reportable segment.
§2 Cenário pessimistaEN
Under a stressed macroeconomic environment where consumer discretionary budgets contract, adult patient case shipments decline, turning Clear Aligner segment revenue growth negative below 0% YoY. Concurrently, low-cost competition in mild malocclusion restricts average selling price expansion. Because unallocated corporate overhead is projected at -$820.00M in FY2026 and -$845.00M in FY2027, operating deleverage rapidly compresses consolidated GAAP operating margin below 11.0% (down from 13.53% in FY2025). If the market simultaneously re-rates Align's cost of capital to reflect its raw beta of 1.7463 with a Ke exceeding 12.67%, intrinsic valuation falls toward $79.13.
Contraction in adult elective clear aligner procedure volumes
Pricing erosion in mild malocclusion cases from alternative aligner offerings
Persistent unallocated corporate expenses unabsorbed by decelerating top-line revenue
Foreign currency translation headwinds depressing international dollar contributions
The Bear scenario models prolonged consumer discretionary spending weakness, leading adult dental patients to postpone elective clear aligner treatments. Competition from lower-cost aligner alternatives limits average selling price growth in mild-to-moderate malocclusion cases, while dental practices lengthen scanner replacement cycles. Fixed corporate overhead and foreign exchange headwinds compound margin compression. Disconfirmation would require Clear Aligner case volume growth re-accelerating across consecutive fiscal quarters.
Como esta tese pode falhar
Macroeconomic Downturn and Adult Orthodontic Treatment Deferral
Clear Aligner revenue of $3,245.40M accounts for 80.43% of total revenue ($4,034.96M). Elective case deferral during consumer discretionary stress turns segment revenue growth negative below 0% YoY, resulting in a modeled -22.5% fair value impact.6,7
FV impact
-5.1%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Sinais de alerta antecipado para monitorar
Os cinco desenvolvimentos que enfraqueceriam a nossa tese de investimento.
Align Technology maintains a narrow competitive moat anchored by its Invisalign brand franchise, proprietary ClinCheck treatment software, and extensive global doctor installation base. With more than 18 million cumulative patients treated, orthodontists and general dental practitioners have accumulated extensive clinical training and operational familiarity with Align's digital systems, creating formidable switching costs. Dental practices face substantial procedural friction, retraining requirements, and patient acceptance hurdles if transitioning to competing clear aligner alternatives.
The company's competitive insulation is reinforced by proprietary SmartTrack material technology and advanced biomechanical algorithms, enabling Align to sustain gross margins of 67.19% in FY2025 ($2,711.01M gross profit on $4,034.96M revenue). This performance maintains a 1,319 basis point premium over the healthcare products industry average of 54.00% and surpasses contact lens manufacturer peer COO at 65.93%. While low-cost alternatives exert pricing pressure in mild malocclusion cases, Align maintains dominant pricing power across complex and comprehensive clinical treatments.
In addition to consumables, Align's Systems and Services segment generated $789.56M in FY2025 revenue and $306.09M in segment operating income (38.77% margin). The deployment of iTero intraoral scanners links restorative and orthodontic dental care directly into Align's digital manufacturing infrastructure. Geographic diversification across Switzerland ($920.59M) and Other International markets ($1,453.19M) accounts for 58.83% of consolidated sales, extending the reach of its digital ecosystem into underpenetrated international territories.
Lucro econômico
Align generated returns on invested capital of 10.39% in FY2025, operating near its moderate cost of equity Ke of 10.67% and WACC of 10.60%. While ROIC reflects post-pandemic operating income normalization to $545.76M, high gross margins of 67.19% and $490.78M in FY2025 free cash flow demonstrate stable underlying economic profitability.2,5,6
7.5/ 10
Narrow
Sources of advantage
01Switching Costs — Over 18 million cumulative patients treated and extensive dental practice integration with ClinCheck software and iTero intraoral scanners create substantial switching costs for dental professionals.Wide
02Intangible Assets — Proprietary SmartTrack material patents and Invisalign brand recognition allow Align to sustain FY2025 gross margins of 67.19%, maintaining a 1,319 bps premium over the healthcare products industry average of 54.00%.Wide
03Network Effects —
Ameaças conhecidas à vantagem competitiva
Ameaça
Gravidade
Cronograma
Mitigação
Low-cost clear aligner competitors and generic direct-to-consumer or dental laboratory alternatives targeting mild-to-moderate malocclusion
medium
12-24 months
Continuous innovation in SmartTrack material, ClinCheck digital features, and integrated restorative dental processes with iTero.
Macroeconomic pressures and consumer discretionary tightening causing prospective adult patients to postpone elective orthodontic procedures
The highlighted cell is Fair value when every assumption sits at its base level ($121.31). Each row and column shows what Fair value becomes when one assumption moves.
The Base scenario assumes modal revenue compounding in low single digits, supported by steady teen Invisalign case adoption and stable international scanner installations. Under this path, operating margins expand modestly as European manufacturing automation takes effect, but unallocated corporate overhead limits operating leverage. Disconfirmation would occur if clear aligner volume contracts or operating margins fail to hold baseline levels by the end of FY2027. At an assessed probability of 60.0%, this scenario yields a target of $121.31, representing an expected return of -17.8% from $147.61 (as of 2026-09-18).
Upgrade to Hold; Re-examine operating margin trajectory and review volume checkpoints without altering capital allocation until margin durability is verified across consecutive quarters.
Gatilho: Clear Aligner case shipments accelerating with operating margins expanding above historical baselines
A material beat driven by comprehensive case re-acceleration and overhead leverage would signal improved cash flow generation and could narrow the gap between $147.61 and $121.31.
Em linha
Maintain the rating; Maintain disciplined position sizing and continue monitoring quarterly Clear Aligner shipment volume and corporate expense trends.
In-line results confirm that revenue growth remains in low single digits while unallocated corporate overhead continues to constrain operating margin expansion, keeping shares trading above $121.31.
Aquém
Downgrade to Sell; Liquidate remaining exposure and re-evaluate only if operations demonstrate sustained operational turnaround.
Gatilho: Clear Aligner revenue contracting year over year with consolidated operating margins compressing further
A miss driven by adult procedure deferrals and average selling price erosion would confirm the bear thesis, accelerating margin degradation and widening the downside gap from $147.61 toward our stress scenarios.
Qualidade dos lucros
Align maintains clean cash generation with operating cash flow consistently exceeding net income. However, high stock-based compensation expenses consume a significant fraction of operating cash flow, and substantial unallocated corporate overhead continues to weigh heavily on consolidated GAAP operating profitability, preventing high gross margins from translating into peer-leading net margins.
Métricas a observar antes do anúncio
01
Métrica:
Clear Aligner shipment volume growth
AtualDecelerating to modest low single digits following post-pandemic normalization.
Por que importa
Drives core segment revenue and establishes whether adult patient demand is stabilizing or deteriorating across major markets.
Capital allocation prioritizes share repurchases and internal reinvestment over dividends, with zero dividend distributions paid. In FY2025, Align deployed $465.94M toward share repurchases, reducing diluted share count from 76,568,000 in FY2023 to 72,588,000 in FY2025. Total debt stands at a modest $114.45M, leaving a substantial position that provides balance sheet safety.
ROIC contracted from historical peaks above 20% to 10.39% in FY2025 as consolidated operating income fell from $976.40M in FY2021 to $545.76M in FY2025 due to unallocated corporate overhead and post-pandemic volume normalization.
ROIC of 10.39% operates near moderate cost of equity Ke of 10.67% and WACC of 10.60%, indicating that economic value creation is currently modest.
Gross margin remains structurally insulated well above healthcare medtech peers
FY2025 gross profit of $2,711.01M on $4,034.96M revenue yielded a 67.19% , exceeding the healthcare industry average of 54.00% and peer COO at 65.93%.
Receita mais recenteUS$ 4 biCAGR da receita +15,8%
Margem operacional13,5%10 períodos fiscais
Fluxo de caixa livre mais recenteUS$ 490,8 miFY2025
Caixa líquidoUS$ 996,4 miFY2025
Detalhamento da demonstração de resultadosComo a escala do negócio se converte em lucro reportado.31 de mar. de 2026
StockMarketAgent.AI
ReceitaUS$ 1,1 triCusto das receitas−US$ 298,8 biLucro brutoUS$ 757,4 biDespesas operacionais−US$ 603,4 biLucro operacionalUS$ 154 biItens não operacionais e impostos−US$ 45,7 biLucro líquidoUS$ 108,3 bi
Dados do histórico financeiro
Receita
US$ 1.056.192.000.000
Custo das receitas
US$ 298.762.000.000
Lucro bruto
US$ 757.430.000.000
Despesas operacionais
US$ 603.417.000.000
Lucro operacional
US$ 154.013.000.000
Itens não operacionais e impostos
-US$ 45.719.000.000
Lucro líquido
US$ 108.294.000.000
Visão geral do balançoComo os ativos reportados são mantidos e financiados no período selecionado.
Align Technology Inc. (ALGN) trades at 11.6x forward earnings against a peer median of 12.0x. Its EV/EBITDA of 10.3x compares with a peer median of 15.8x. The comparison uses 4 peers: The Cooper Companies Inc., Bio-Techne Corporation, DaVita Inc. and Solventum Corporation, as of 2026-09-20.
§10 Setor e cicloEN
Fase do ciclo
Contraction
Industry capital intensity benchmarks indicate a capex-to-revenue ratio of 4.5% and capex-to-depreciation of 0.8x. Align's FY2025 capex of $102.45M on $4,034.96M revenue represents a 2.54% capex-to-revenue ratio, and capex-to-depreciation stands at 0.43x against depreciation of $237.44M, down significantly from FY2021 capex of $401.10M. Because capacity, supply, lead-time, and customer-concentration evidence is unavailable, the cycle view is demand-led and evidence-limited.6
Ciclo de alta
Adolescent and teen orthodontic adoption accelerates, digital scanner replacement cycles shorten with next-generation imaging platforms, and international penetration expands across underpenetrated dental markets.
Ciclo de baixa
Persistent consumer inflation and high interest rates lead adult patients to defer elective out-of-pocket dental procedures, while corporate overhead remains rigid and low-cost aligners pressure non-comprehensive case pricing.
Tendências seculares
Tendência
Impacto
Nota
Digitization of Orthodontic and Restorative Dental Practices
positive
Transition from traditional physical impressions to intraoral scanning drives recurring clear aligner submissions and practice integration.
Direct-to-Consumer and Low-Cost Laboratory Aligner Proliferation
negative
Commoditizes mild malocclusion cases and limits average selling price expansion across non-comprehensive treatments.
Expansion of Clear Aligner Eligibility to Teens and Growing Children
positive
Posicionamento
Align maintains dominant market share in orthodontic clear aligners and intraoral digital scanners, positioning the firm to capture long-term digital dentistry adoption while remaining vulnerable in the near term to discretionary spending contractions.
§11 Gestão de posiçãoEN
Dimensionamento
Under our Reduce rating, establishing new long exposure is not warranted because shares trade at $147.61, representing a 21.68% premium over Fair value of $121.31. Investors holding existing positions should underweight or trim holdings.4
Risco
Risk management for Align Technology requires rigorous defense against consumer discretionary cyclicality and corporate operating deleverage. With shares trading at $147.61 versus our Fair value of $121.31, asymmetric downside risk dominates. Portfolios should maintain an underweight stance, utilize any valuation surges to trim holdings, and enforce strict quarterly checkpoints on case volumes and operating margins.
Tranches de entrada
Nível
Ação
Por quê
Below $103.08
Re-evaluate valuation discount
A pullback to the discounted earnings valuation anchor of $103.08 would provide an adequate margin of safety to re-assess risk-reward dynamics.
Below $80.03
Consider initial accumulation if fundamentals stabilize
Approaching the multi-stage moat fade anchor of $80.03 would price in severe margin degradation, creating an attractive entry point if clear aligner volume growth re-accelerates.
Shares trade at $147.61, representing an 17.82% premium to our Fair value of $121.31 and offering zero margin of safety against earnings deceleration.4
Growth Investor
Avoid
Revenue growth has decelerated to low single digits (3.26% consensus for FY2026), while adult orthodontic procedure deferral limits near-term multiple expansion.1
Current Position Holders
Hold
Investors with existing positions should hold only with a strict 6% trailing stop while systematically trimming into price strength toward $155.00.
§14 Recomendação finalEN
Ação
Reduzir
We recommend reducing exposure to Align Technology as the report-date price of $147.61 trades at a 21.7% premium to our Fair value of $121.31. While the core Invisalign ecosystem and doctor switching costs remain intact, post-pandemic revenue growth deceleration to 3-4% and substantial unallocated corporate overhead constrain earnings expansion.7
Investors should capitalize on trading strength to trim existing positions and redeploy capital into opportunities with a stronger margin of safety. New purchases should be deferred until valuation compresses toward intrinsic value or until operating leverage sustainably re-emerges.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 char
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-12-31 · Published 2026-07-29 · cited for 1 figureCited in Perspectivas dos investidores
Market and peer researchData as of 2026-09-20 · Published 2026-09-20 · Provider-adjusted · cited for 1 figureCited in Vantagem competitiva, Histórico financeiro
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Margin Degradation from Pricing Pressure and Rigid SG&A
Consolidated operating margin fell to 13.53% in FY2025 from 15.19% in 2024 and 16.66% in 2023. Continued ASP erosion in mild malocclusion combined with -$820M in corporate consolidation adjustments pushes operating margin below 11.0%, resulting in an estimated -18.0% fair value impact.6
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Required Cost of Capital Surge from Beta Re-Rating
Moderate Ke is 10.67% using adjusted beta of 1.385, but raw beta is 1.7463. If the market prices Align at strict raw beta Ke of 12.17% plus credit spread widening, Ke exceeds 12.67%, driving a -17.5% fair value contraction.2
FV impact
-10.8%
Cost of capital 2 points higher
Trigger
Within 12 months
Demonstrates failure of manufacturing automation to offset unallocated corporate SG&A and pricing erosion.
Excessive share-based compensation dilutes equity value and signals unsustainable non-cash compensation drag on economic owner earnings.
Atual:31.33% (FY2025 reported)
Alerta se> 35.0%
An international installation base across Europe and Asia-Pacific generated $2,373.78M in FY2025 international revenue, reinforcing scanner network adoption and clinical case data feedback loops.
Moderate
high
6-18 months
Expanding teen segment penetration, insurance reimbursement integration, and flexible practice financing options.
Foreign exchange volatility and regional macroeconomic deceleration across European and emerging dental markets
medium
Ongoing
Natural geographic expense hedging through regional manufacturing hubs in Poland and Mexico.7
Stabilization of discretionary healthcare consumer spending across North America and Europe
The Bull scenario reflects accelerated adolescent and teen clear aligner penetration, rapid adoption of the latest iTero intraoral scanner platform, and faster international expansion across underpenetrated emerging dental markets. Fixed-cost absorption in manufacturing hubs accelerates operating margin expansion toward historical peaks. This path would be disconfirmed if adult case deferrals spread to the teen cohort or if scanner placement cadence decelerates. With an assessed probability of 20.0%, this outcome supports a target of $121.34, offering a return of -17.8% from $147.61 (as of 2026-09-18).
Por que importa
Reveals whether manufacturing automation and regional footprint efficiency are offsetting unallocated corporate overhead and price competition.
AtualAccounts for the majority of consolidated revenue but remains vulnerable to regional macroeconomic conditions.
Por que importa
Determines whether underpenetrated dental markets in Europe and Asia-Pacific can sustain global volume expansion despite foreign exchange translation friction.
04
Métrica:
iTero intraoral scanner installation cadence
AtualDelivers high segment operating profitability while experiencing extended capital replacement cycles among dental practices.
Por que importa
Expands digital integration and clinical case submissions from general dentists and orthodontists.
Align retains pricing power and manufacturing scale in comprehensive cases, preventing competitive gross margin erosion.
Unallocated corporate expenses impose a severe drag on consolidated operating profitability
While Clear Aligner operating income reached $1,034.79M (31.88% margin) and Systems & Services reached $306.09M (38.77% margin), consolidated operating income was only $545.76M (13.53% margin) due to corporate consolidation expenses of -$795.13M, projected at -$820.00M in FY2026.
Operating margins will remain constrained near 13.5% to 14.4% unless corporate overhead is restructured.
